Literature DB >> 893418

A simple generalized equation for the analysis of multiple inhibitions of Michaelis-Menten kinetic systems.

T C Chou, P Talalay.   

Abstract

The summation of the effects of two or more reversible inhibitors of various types on the initial velocity of enzyme systems obeying Michaelis-Menten kinetics is described by the the general relation: (formula: see text) wherein v1,2,3...n is the velocity of reaction in the simultaneous presence of n inhibitors, vi is the velocity observed in the presence of each individual inhibitor, and v0 is the velocity in the absence of inhibition. The derivation is based on the assumption that each enzyme species can combine with no more than one of the inhibitors (i.e. the inhibitors are mutually exclusive). The above relationship holds irrespective of the number of inhibitors, the type of inhibition (competitive, noncompetitive, or uncompetitive), or the kinetic mechanism (sequential or ping-pong) of the enzyme reaction under consideration. Deviations from this equality define synergism or antagonism of inhibitors depending on whether the value of the left side of the above equation is greater or smaller than the right, respectively. Knowledge of the kinetic constants for substrates and inhibitors is not required. If two or more inhibitors act independently (i.e. are not mutually exclusive), their combined effects are necessarily synergistic. Under certain circumstances, described in the text, mutually nonexclusive inhibitors obey the fractional velocity product relationship: v1,2,3...n/v0 = (v1/v0) x (v2/v0) x (v3/v0)...(vn/v0).

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 893418

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.486


  110 in total

1.  Synergy determination issues.

Authors:  Ting-Chao Chou
Journal:  J Virol       Date:  2002-10       Impact factor: 5.103

2.  The mass-action law based algorithm for cost-effective approach for cancer drug discovery and development.

Authors:  Ting-Chao Chou
Journal:  Am J Cancer Res       Date:  2011-08-05       Impact factor: 6.166

3.  Enhanced exposure of human immunodeficiency virus type 1 primary isolate neutralization epitopes through binding of CD4 mimetic compounds.

Authors:  Kazuhisa Yoshimura; Shigeyoshi Harada; Junji Shibata; Makiko Hatada; Yuko Yamada; Chihiro Ochiai; Hirokazu Tamamura; Shuzo Matsushita
Journal:  J Virol       Date:  2010-05-26       Impact factor: 5.103

4.  Inhibition of human immunodeficiency virus in vitro by combinations of 3'-azido-3'-deoxythymidine and foscarnet.

Authors:  R Koshida; L Vrang; G Gilljam; J Harmenberg; B Oberg; B Wahren
Journal:  Antimicrob Agents Chemother       Date:  1989-05       Impact factor: 5.191

5.  Inhibition of Ubiquitin-Specific Protease 14 Suppresses Cell Proliferation and Synergizes with Chemotherapeutic Agents in Neuroblastoma.

Authors:  Yang Yu; Yanling Zhao; Yihui Fan; Zhenghu Chen; Hui Li; Jiaxiong Lu; Kevin Guo; Sarah E Woodfield; Sanjeev A Vasudevan; Jianhua Yang; Jed G Nuchtern
Journal:  Mol Cancer Ther       Date:  2019-04-08       Impact factor: 6.261

6.  Synergy and antagonism of promiscuous inhibition in multiple-compound mixtures.

Authors:  Brian Y Feng; Brian K Shoichet
Journal:  J Med Chem       Date:  2006-04-06       Impact factor: 7.446

7.  Increased expression of P-glycoprotein is associated with doxorubicin chemoresistance in the metastatic 4T1 breast cancer model.

Authors:  Lili Bao; Aliyya Haque; Kamilah Jackson; Sidhartha Hazari; Krzysztof Moroz; Rachna Jetly; Srikanta Dash
Journal:  Am J Pathol       Date:  2011-02       Impact factor: 4.307

8.  In vitro activity and preclinical profile of TMC435350, a potent hepatitis C virus protease inhibitor.

Authors:  Tse-I Lin; Oliver Lenz; Gregory Fanning; Thierry Verbinnen; Frédéric Delouvroy; Annick Scholliers; Katrien Vermeiren; Asa Rosenquist; Michael Edlund; Bertil Samuelsson; Lotta Vrang; Herman de Kock; Piet Wigerinck; Pierre Raboisson; Kenneth Simmen
Journal:  Antimicrob Agents Chemother       Date:  2009-01-26       Impact factor: 5.191

9.  Preparation and evaluation of self-nanoemulsifying tablets of carvedilol.

Authors:  Enas A Mahmoud; Ehab R Bendas; Magdy I Mohamed
Journal:  AAPS PharmSciTech       Date:  2009-02-24       Impact factor: 3.246

10.  Combination of bendamustine and entinostat synergistically inhibits proliferation of multiple myeloma cells via induction of apoptosis and DNA damage response.

Authors:  Bo Cai; Hui Lyu; Jingcao Huang; Shuiliang Wang; Choon-Kee Lee; Chunji Gao; Bolin Liu
Journal:  Cancer Lett       Date:  2013-02-28       Impact factor: 8.679

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.